KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells
Open Access
- 6 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 5048
Abstract
Epigenetic alterations my play a role in the aggressive behavior of Non-Small Cell Lung Cancer (NSCLC). Treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) has been reported to interfere with the proliferative and invasive potential of NSCLC cells. In addition, the DNA methyltransferase inhibitor azacytidine (AZA, vidaza) can modulate the levels of the metastasis suppressor KiSS-1. Thus, since cisplatin is still clinically available for NSCLC therapy, the aim of this study was to evaluate drug combinations between cisplatin and SAHA as well as AZA using cisplatin-sensitive H460 and -resistant H460/Pt NSCLC cells in relation to KiSS-1 modulation. An analysis of drug interaction according to the Combination-Index values indicated a more marked synergistic effect when the exposure to SAHA or AZA preceded cisplatin treatment with respect to a simultaneous schedule. A modulation of proteins involved in apoptosis (p53, Bax) was found in both sensitive and resistant cells, and compared to the treatment with epigenetic agents alone, the combination of cisplatin and SAHA or AZA increased apoptosis induction. The epigenetic treatments, both as single agents and in combination, increased the release of KiSS-1. Finally, the exposure of cisplatin-sensitive and -resistant cells to the kisspeptin KP10 enhanced cisplatin induced cell death. The efficacy of the combination of SAHA and cisplatin was tested in vivo after subcutaneous inoculum of parental and resistant cells in immunodeficient mice. A significant tumor volume inhibition was found when mice bearing advanced tumors were treated with the combination of SAHA and cisplatin according to the best schedule identified in cellular studies. These results, together with the available literature, support that epigenetic drugs are amenable for the combination treatment of NSCLC, including patients bearing cisplatin-resistant tumors.Keywords
Funding Information
- Fondazione Cariplo-Regione Lombardia (#2016-1019)
- AIRC (#2016-1019)
This publication has 44 references indexed in Scilit:
- The promises and pitfalls of epigenetic therapies in solid tumoursEuropean Journal of Cancer, 2009
- Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin ReceptorEuropean Urology, 2009
- Lung CancerNew England Journal of Medicine, 2008
- Covalent modifications of histones during development and disease pathogenesisNature Structural & Molecular Biology, 2007
- Drug Resistance and the Solid Tumor MicroenvironmentJNCI: Journal of the National Cancer Institute, 2007
- Requirement of KISS1 Secretion for Multiple Organ Metastasis Suppression and Maintenance of Tumor DormancyJNCI: Journal of the National Cancer Institute, 2007
- Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs☆Drug Resistance Updates, 2007
- Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cellsInternational Journal of Oncology, 2005
- Translating the Histone CodeScience, 2001
- KiSS-1, a Novel Human Malignant Melanoma Metastasis-Suppressor GeneJNCI: Journal of the National Cancer Institute, 1996